Scarica l'app Stockscreener
12.00
2.65%
0.31
Dopo l'orario di chiusura:
12.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$11.69
Aprire:
$11.42
Volume 24 ore:
558.25K
Relative Volume:
1.35
Capitalizzazione di mercato:
$236.61M
Reddito:
$244.06M
Utile/perdita netta:
$87.01M
Rapporto P/E:
6.5887
EPS:
1.8213
Flusso di cassa netto:
$105.95M
1 W Prestazione:
+8.30%
1M Prestazione:
-13.73%
6M Prestazione:
-22.98%
1 anno Prestazione:
+19.52%
Intervallo 1D:
$11.30
$12.03
Intervallo di 1 settimana:
$10.41
$12.03
Portata 52W:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
12.00 | 236.61M | 244.06M | 87.01M | 105.95M | 1.8213 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report? - Yahoo Finance
The Technical Signals Behind (KROS) That Institutions Follow - Stock Traders Daily
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? - MSN
KROS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock? - qz.com
Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer - Stock Titan
Vanguard disaggregates holdings; reports 0 KROS shares (KROS) - Stock Titan
Fed Meeting: What are Keros Therapeutics Incs technical support levels2026 Dividend Review & Fast Gain Swing Alerts - baoquankhu1.vn
KROS stock: What to know about Rinvatercept in DMD - MSN
Chart Watch: What is Keros Therapeutics Incs P E ratio telling us2026 Year in Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Institution Moves: Can Keros Therapeutics Inc weather a recessionM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Published on: 2026-03-25 15:00:50 - baoquankhu1.vn
KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart.com
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from S&P Biotechnology Select Industry Index - MarketScreener
Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones - Stock Traders Daily
Quarterly Trades: Is now the right time to enter Keros Therapeutics Inc2026 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
Block Trades: Will RIVN benefit from current market trendsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept stand out in the DMD market? - MSN
Targets Report: Is Keros Therapeutics Inc likely to announce a buyback2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn
KROS: Does the Discounted Book Value Represent a Value Trap? - Bitget
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026 - sharewise.com
KROS Stock: Key Information on Rinvatercept for DMD - Bitget
KROS Pipeline Catalysts: DMD Phase II Progress and ALS Strategy for 2026 - Bitget
KROS Stock: What to Know About Rinvatercept in DMD - Yahoo Finance
KROS PE Ratio & Valuation, Is KROS Overvalued - Intellectia AI
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart
Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com
Keros Therapeutics (KROS) director submits initial Form 3 ownership - Stock Titan
Director adds Keros Therapeutics (NASDAQ: KROS) shares under 10b5-1 plan - Stock Titan
Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily
Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL) - The Globe and Mail
Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - minichart.com.sg
Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times
Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView
Keros (NASDAQ: KROS) moves rinvatercept toward Phase 2 in ALS, DMD - Stock Titan
Keros Therapeutics Presents Additional Clinical Data from - GlobeNewswire
Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - MarketBeat
Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn
Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir
Keros Therapeutics, Inc. (KROS) reports Q4 loss, misses revenue estimates - MSN
Investment Review: Is now the right time to enter Keros Therapeutics IncChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):